HMH Holding Inc. reports its first earnings as a public company on May 1, arriving with a wave of fresh analyst coverage and a stock that has already moved sharply higher.
The positioning picture is relaxed rather than charged. Short interest is minimal — FINRA's latest fortnightly data shows fewer than 245,000 shares short, with days to cover at just 1.0. Utilization has collapsed from a peak of 37% in early April to just 15% now, and borrow costs have followed the same trajectory: the cost to borrow tumbled from above 22% on April 2 to 1.46% by April 24 — a near-90% drop in under four weeks. The ORTEX short score has also fallen sharply, from the low-to-mid 50s in early April to 32 now, reflecting a broad retreat by short sellers. The stock itself has responded: HMH closed at $21.00 on April 27, up 4.3% on the day and 9.1% on the week.
The defining development heading into the print is the analyst initiation wave. Five firms — Citigroup, JP Morgan, Stifel, Piper Sandler, and Evercore ISI — all initiated coverage on April 27, the day before earnings. Every single one came in bullish, with ratings of Buy, Overweight, or Outperform across the board. Price targets range from $26 (JP Morgan) to $32 (Piper Sandler), with the consensus mean landing at $28.75 — implying roughly 37% upside to the current price. Citigroup's Scott Gruber set a $30 target, and Piper Sandler's Derek Podhaizer was the most aggressive at $32. The uniform bullish stance at initiation is notable. It removes any obvious near-term analyst-driven headwind, but it also means the stock enters earnings with expectations already set high on the Street.
The ownership data reinforces the early-stage profile. Encompass Capital Advisors holds 7.6% of shares, and Citadel Advisors added a 6.3% stake — both positions reported as new entries. Alongside these institutional anchors, the CEO, CTO, and Chief Commercial Officer all made open-market purchases at $20 per share on April 2, a combined $380,000 in cash buying from the C-suite just weeks after listing. These are small absolute amounts, but the broad-based, at-market insider buying adds a layer of alignment ahead of the first public earnings release.
The May 1 print will be the first real test of whether HMH's operational and financial profile justifies a unanimous bullish consensus initiated just days before the results — and whether the $28–$32 target range holds up once the Street has actual numbers to work with.
See the live data behind this article on ORTEX.
Open HMH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
